SEC filing · 8-K

Integra Lifesciences Holdings Corp: Quarterly results

Integra LifeSciences announced preliminary third-quarter financial results and lowered its full-year 2026 outlook due to supply disruptions from flooding at its Cincinnati facility.

Filed October 2, 2026

Negative for the company

What happened

Preliminary third-quarter reported revenue is expected to be between $410 million to $412 million, and adjusted earnings per diluted share is expected to be $0.55 to $0.59.

The full interpretation is in the app

Why it matters, the key numbers from the document and what to watch next: the full interpretation of every report is part of Pro.

Read the full interpretation

Read the original

Filing document on SEC.gov Press release (EX-99.1) All documents of this filing

Back to Integra Lifesciences Holdings Corp

Summary generated automatically from the filing text and checked against it: every number above is printed in the document. It describes the filing and is not investment advice. Read the original before relying on it.